Idarucizumab: An anticoagulant reversal agent for dabigatran

Anthony F. T. Brown, Harshal Nandurkar

Research output: Contribution to journalReview ArticleOtherpeer-review


Idarucizumab is a specific reversal agent for the novel oral anticoagulant (NOAC) dabigatran. Idarucizumab is indicated when rapid, complete and sustained reversal of dabigatran’s anticoagulant effect is needed, such as when the patient requires emergency surgery or an urgent procedure, or has life-threatening or uncontrolled bleeding.
Original languageEnglish
Pages (from-to)63-65
Number of pages3
JournalMedicine Today
Issue number11
Publication statusPublished - 1 Nov 2016

Cite this